-
Je něco špatně v tomto záznamu ?
The plausible association of MTHFR and ADORA2A polymorphisms with nodules in rheumatoid arthritis patients treated with methotrexate
T. Soukup, M. Dosedel, J. Nekvindova, A. Antonin Kubena, I. Tacheci, J. Duintjer Tebbens, J. Vlcek, P. Bradna, I. Barvik, P. Pavek,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- antirevmatika aplikace a dávkování škodlivé účinky MeSH
- dospělí MeSH
- genetická predispozice k nemoci MeSH
- genetické asociační studie MeSH
- genotyp MeSH
- jednonukleotidový polymorfismus * MeSH
- lidé středního věku MeSH
- lidé MeSH
- methotrexát aplikace a dávkování škodlivé účinky MeSH
- methylentetrahydrofolátreduktasa (NADPH2) genetika MeSH
- průřezové studie MeSH
- receptor adenosinový A2A genetika MeSH
- revmatoidní artritida farmakoterapie MeSH
- revmatoidní uzlíky chemicky indukované genetika MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVE: The treatment of rheumatoid arthritis (RA) patients with methotrexate (MTX) is linked to the development or progression of rheumatoid nodules. The aim of this study was to determine whether folate and adenosine pathways-related single nucleotide polymorphisms might be predictive of increased nodule formation in RA patients treated with oral MTX. METHODS: A total of 185 Caucasian RA patients were enrolled in this cross-sectional study, all of whom fulfilled the 1987 RA criteria of the American College of Rheumatology; each patient had a history of MTX treatment. RESULTS: A higher frequency of the MTHFR 1298AA genotype was found in 17 (70.8%) of 24 patients with general nodules [odds ratio (OR)=3.08, 95% confidence interval (CI): 1.20-7.69] and in 14 (73.7%) of 19 patients who developed nodules during MTX treatment (OR=3.55, 95% CI: 1.22-10.32). In contrast, a negative association with nodules during MTX treatment (OR=0.29, 95% CI: 0.08-1.10) was found for 19 (79.2%) patients with the TT genotype (rs2298383) in the adenosine A2a receptor gene (ADORA2A). However, the significance did not remain upon correction for multiple testing. The combination of MTHFR 1298AA along with ADORA2A rs2298383 CC or CT genotypes occurring in one-third of RA patients showed a higher frequency of general nodules 15/59 (25.4%) as well as developing nodules during MTX treatment 13/59 (22.0%) in comparison with the overall studied group: 24/185 (13.0%) and 19/185 (10.3%), respectively. CONCLUSION: This exploratory study indicates for the first time a plausible association of adenosine and folate pathways single nucleotide polymorphisms in nodules' etiopathogenesis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016915
- 003
- CZ-PrNML
- 005
- 20180521094846.0
- 007
- ta
- 008
- 180515s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/FPC.0000000000000256 $2 doi
- 035 __
- $a (PubMed)27846189
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Soukup, Tomas $u aSecond Department of Internal Medicine - Gastroenterology and Rheumatology, Faculty of Medicine bInstitute of Clinical Biochemistry and Diagnostics, University Hospital Departments of cSocial and Clinical Pharmacy dBiophysics and Physical Chemistry ePharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove fInstitute of Physics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic.
- 245 14
- $a The plausible association of MTHFR and ADORA2A polymorphisms with nodules in rheumatoid arthritis patients treated with methotrexate / $c T. Soukup, M. Dosedel, J. Nekvindova, A. Antonin Kubena, I. Tacheci, J. Duintjer Tebbens, J. Vlcek, P. Bradna, I. Barvik, P. Pavek,
- 520 9_
- $a OBJECTIVE: The treatment of rheumatoid arthritis (RA) patients with methotrexate (MTX) is linked to the development or progression of rheumatoid nodules. The aim of this study was to determine whether folate and adenosine pathways-related single nucleotide polymorphisms might be predictive of increased nodule formation in RA patients treated with oral MTX. METHODS: A total of 185 Caucasian RA patients were enrolled in this cross-sectional study, all of whom fulfilled the 1987 RA criteria of the American College of Rheumatology; each patient had a history of MTX treatment. RESULTS: A higher frequency of the MTHFR 1298AA genotype was found in 17 (70.8%) of 24 patients with general nodules [odds ratio (OR)=3.08, 95% confidence interval (CI): 1.20-7.69] and in 14 (73.7%) of 19 patients who developed nodules during MTX treatment (OR=3.55, 95% CI: 1.22-10.32). In contrast, a negative association with nodules during MTX treatment (OR=0.29, 95% CI: 0.08-1.10) was found for 19 (79.2%) patients with the TT genotype (rs2298383) in the adenosine A2a receptor gene (ADORA2A). However, the significance did not remain upon correction for multiple testing. The combination of MTHFR 1298AA along with ADORA2A rs2298383 CC or CT genotypes occurring in one-third of RA patients showed a higher frequency of general nodules 15/59 (25.4%) as well as developing nodules during MTX treatment 13/59 (22.0%) in comparison with the overall studied group: 24/185 (13.0%) and 19/185 (10.3%), respectively. CONCLUSION: This exploratory study indicates for the first time a plausible association of adenosine and folate pathways single nucleotide polymorphisms in nodules' etiopathogenesis.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a antirevmatika $x aplikace a dávkování $x škodlivé účinky $7 D018501
- 650 _2
- $a revmatoidní artritida $x farmakoterapie $7 D001172
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetické asociační studie $7 D056726
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a methotrexát $x aplikace a dávkování $x škodlivé účinky $7 D008727
- 650 _2
- $a methylentetrahydrofolátreduktasa (NADPH2) $x genetika $7 D042965
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a jednonukleotidový polymorfismus $7 D020641
- 650 _2
- $a receptor adenosinový A2A $x genetika $7 D043705
- 650 _2
- $a revmatoidní uzlíky $x chemicky indukované $x genetika $7 D012218
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dosedel, Martin
- 700 1_
- $a Nekvindova, Jana
- 700 1_
- $a Antonin Kubena, Ales
- 700 1_
- $a Tacheci, Ilja
- 700 1_
- $a Duintjer Tebbens, Jurjen
- 700 1_
- $a Vlcek, Jiri
- 700 1_
- $a Bradna, Petr
- 700 1_
- $a Barvik, Ivan
- 700 1_
- $a Pavek, Petr
- 773 0_
- $w MED00189565 $t Pharmacogenetics and genomics $x 1744-6880 $g Roč. 27, č. 2 (2017), s. 43-50
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27846189 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180521095028 $b ABA008
- 999 __
- $a ok $b bmc $g 1300539 $s 1013755
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 27 $c 2 $d 43-50 $i 1744-6880 $m Pharmacogenetics and genomics $n Pharmacogenet Genomics $x MED00189565
- LZP __
- $a Pubmed-20180515
